In January 2013, an announcement by Mirna Therapeutics, a Texas-based company founded in 2007, that focuses on macroRNA in therapeutics, confirmed that Seattle Genetics co-founder, Dr. Clay Siegall, who is also the Chairman of the Board of Directors, and the current Chief Executive Officer, would be appointed as a member of the board of directors, as an outside Director. Mirna Therapeutics currently focus on cancer research and Dr. Seagull has a background in the subject.
Seattle Genetics is a leading biotechnology company that works on developing both Clinical and Pre-clinical products. The company is mainly based on research, scientific innovations, and drug development procedures. On drug development practises, the company focuses on developing ADC technology, which reduces toxic effects of chemotherapy and enhances antitumor activity. The ADC technology is divided into different programs. SGN-CD33A is used for acute myeloid leukemia, whereas SGN-CD 19A is used for non-Hodgkin lymphoma. ADCETRIS therapy, used for Lymphoma patients has treated over 15000 patients worldwide. SEA-CD40 is scheduled to be used for solid tumours and was the first engineered Antibody to be developed using SEA technology.
Dr. Clay Siegall, the current president and C.E.O of Mirna Therapeutics said the company is excited to work with Dr. Seagull on the Board of Directors, with his expertise in cancer research. He also said they expect Dr. Siegall to assist through guiding them in advancements and development of their micro-based therapeutics. Seattle Genetics was co-founded by Dr. Siegall in the year 1998. Mr. Clay acquired his Bachelors in science Zoology and later went on to pursue his Ph.D. in Genetics at George Washington University. He worked for the National Cancer Institute, National Institute of Health, as well as Bristol- Myers Squibb Pharmaceutical Research Institute before finally co- founding Seattle Genetics.
His has vast expertise and experience in leading Seattle Genetics Company to successfully create Antibody-based therapies for Cancer patients whose medical needs had been sidelined. Read More: